Skip to content
OpenCapital
Get started
Moderna logo

Moderna (MRNA) Q1 2024 Earnings

MRNA·Reported May 2, 2024·Before market open

Moderna reported Q1 2024 revenue of $167.0M, beat analyst consensus of $93.3M by $73.7M. Diluted EPS came in at $-3.07, beat the $-3.56 consensus by $0.49. Moderna reports across 3 business segments, led by Infectious Disease Vaccines, Oncology and Individualized Neoantigen Therapies, and Rare Disease and Other Therapeutics.

Revenue
$167.0Mbeat by $73.7M
Consensus: $93.3M
Diluted EPS
$-3.07beat by $0.49
Consensus: $-3.56
SEC

SEC Filings

Earnings release8-K · 0001682852-24-000023
Quarterly report10-Q · 0001682852-24-000027

Financial Snapshot

Trailing eight quarters through Q1 2024

View all metrics

Q1 2024 Earnings FAQ

Common questions about Moderna's Q1 2024 earnings report.

Moderna (MRNA) reported Q1 2024 earnings on May 2, 2024 before market open.

Moderna reported revenue of $167.0M and diluted EPS of $-3.07 for Q1 2024.

Revenue beat the consensus estimate of $93.3M by $73.7M. EPS beat the consensus estimate of $-3.56 by $0.49.

You can read the 8-K earnings release (0001682852-24-000023) and the 10-Q periodic report (0001682852-24-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.